Skip to main content
Top
Published in: Diagnostic Pathology 1/2014

Open Access 01-12-2014 | Research

Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma

Authors: Tomoko Yamagishi, Katsuhiko Shimizu, Nobuaki Ochi, Hiromichi Yamane, Isao Irei, Yoshito Sadahira, Nagio Takigawa, Mikio Oka, Masao Nakata

Published in: Diagnostic Pathology | Issue 1/2014

Login to get access

Abstract

Background

Non-small cell lung cancers (NSCLCs) are frequently heterogeneous and in approximately 70% of cases, NSCLCs are diagnosed and staged by small biopsies or cytology rather than by examination of surgically resected specimens. Thus, in most patients, the diagnosis is established based on examination of preoperative specimens alone. Recently, classification of NSCLC into pathologic subtypes has been shown to be important for selecting the appropriate systemic therapy, from both the point of view of treatment efficacy and prevention of toxicity.

Methods

We retrospectively reviewed the data of 225 patients to compare the preoperative classification of the NSCLC subtype on biopsy specimens with the postoperative classification based on examination of the resected specimens, in order to compare the accuracy of the two for the diagnosis of various histological subtypes of NSCLC.

Results

In 169 of the 225 (75.1%) patients, the preoperative diagnosis was definite malignancy. Histologically, the final pathologic diagnosis made from the surgical specimens was adenocarcinoma (ADC) in 169 patients, and in 75.5% of these cases, the diagnosis was concordant with the preoperative diagnosis. Among the patients who had squamous cell carcinoma (SQC) in the preoperative specimens, the diagnosis was concordant with the preoperative diagnosis in 65.7% of cases. Misclassified preoperative biopsies included an even number of SQCs and ADCs, with all the misclassified biopsies being ADCs morphologically mimicking SQC due to solid growth. Significantly higher specificity, negative predictive value and accuracy were observed for the diagnosis of SQC.

Conclusions

Our study suggested that the concordance rates for diagnosis of the NSCLC subtypes, especially the "squamous" or "non-squamous" histologies, between preoperative and surgical specimens were satisfactory, as compared with previous reports. Therefore, pretreatment diagnosis of lung cancer using small samples is reasonable for selecting the optimal treatment. However, in order not to lose the opportunity for selecting an effective treatment, we should be aware that the diagnosis in preoperative small samples might be different from that based on examination of the surgical specimens.

Virtual Slides

Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90.PubMedCrossRef
2.
go back to reference Crino L, Weder W, Van Meerbeeck J, Felip E: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010, 21: 103-1.CrossRef Crino L, Weder W, Van Meerbeeck J, Felip E: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010, 21: 103-1.CrossRef
3.
go back to reference Itaya T, Yamaoto N, Ando M, Ebisawa M, Nakamura Y, Murakami H, Asai G, Endo M, Takahashi T: Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci. 2007, 98: 226-230.PubMedCrossRef Itaya T, Yamaoto N, Ando M, Ebisawa M, Nakamura Y, Murakami H, Asai G, Endo M, Takahashi T: Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci. 2007, 98: 226-230.PubMedCrossRef
4.
go back to reference Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, et al.: International association for the study of lung Cancer/American thoracic Society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011, 6: 244-285.PubMedPubMedCentralCrossRef Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, et al.: International association for the study of lung Cancer/American thoracic Society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011, 6: 244-285.PubMedPubMedCentralCrossRef
5.
go back to reference Shah PL, Singh S, Bower M, Livni N, Padley S, Nicholson AG: The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer. J Thorac Oncol. 2006, 1: 324-327.PubMedCrossRef Shah PL, Singh S, Bower M, Livni N, Padley S, Nicholson AG: The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer. J Thorac Oncol. 2006, 1: 324-327.PubMedCrossRef
6.
go back to reference Einhorn LH: First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology?. J Clin Oncol. 2008, 20: 3485-3486.CrossRef Einhorn LH: First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology?. J Clin Oncol. 2008, 20: 3485-3486.CrossRef
7.
go back to reference Stinchcombe TE, Grilley-Olson JE, Socinski MA: If histology matters. J Clin Oncol. 2010, 28: 1810-1812.PubMedCrossRef Stinchcombe TE, Grilley-Olson JE, Socinski MA: If histology matters. J Clin Oncol. 2010, 28: 1810-1812.PubMedCrossRef
8.
go back to reference Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, De Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non–small-cell lung cancer. J Clin Oncol. 2008, 26: 3543-3551.PubMedCrossRef Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, De Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non–small-cell lung cancer. J Clin Oncol. 2008, 26: 3543-3551.PubMedCrossRef
9.
go back to reference Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139.PubMedCrossRef Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139.PubMedCrossRef
10.
go back to reference Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304: 1497-1500.PubMedCrossRef Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304: 1497-1500.PubMedCrossRef
11.
go back to reference Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009, 361: 947-957.PubMedCrossRef Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009, 361: 947-957.PubMedCrossRef
12.
go back to reference Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004, 22: 2184-2191.PubMedCrossRef Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004, 22: 2184-2191.PubMedCrossRef
13.
go back to reference Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM: Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol. 2000, 53: 537-540.PubMedPubMedCentralCrossRef Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM: Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol. 2000, 53: 537-540.PubMedPubMedCentralCrossRef
14.
go back to reference Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol. 2013, 8: 823-859.PubMedPubMedCentralCrossRef Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol. 2013, 8: 823-859.PubMedPubMedCentralCrossRef
15.
go back to reference Cataluna JJ, Perpina M, Greses JV, Calvo V, Padilla JD, París F: Cell type accuracy of bronchial biopsy specimens in primary lung cancer. Chest. 1996, 109: 1199-1203.PubMedCrossRef Cataluna JJ, Perpina M, Greses JV, Calvo V, Padilla JD, París F: Cell type accuracy of bronchial biopsy specimens in primary lung cancer. Chest. 1996, 109: 1199-1203.PubMedCrossRef
16.
go back to reference Matsuda M, Horai T, Nakamura S, Nishio H, Sakuma T, Ikegami H, Tateishi R: Bronchial brushing and bronchial biopsy: comparison of diagnostic accuracy and cell typing reliability in lung cancer. Thorax. 1986, 41: 475-478.PubMedPubMedCentralCrossRef Matsuda M, Horai T, Nakamura S, Nishio H, Sakuma T, Ikegami H, Tateishi R: Bronchial brushing and bronchial biopsy: comparison of diagnostic accuracy and cell typing reliability in lung cancer. Thorax. 1986, 41: 475-478.PubMedPubMedCentralCrossRef
17.
go back to reference Rudd RM, Gellert AR, Boldy DA, Studdy PR, Pearson MC, Geddes DM: Bronchoscopic and percutaneous aspiration biopsy in the diagnosis of bronchial carcinoma cell type. Thorax. 1982, 37: 462-465.PubMedPubMedCentralCrossRef Rudd RM, Gellert AR, Boldy DA, Studdy PR, Pearson MC, Geddes DM: Bronchoscopic and percutaneous aspiration biopsy in the diagnosis of bronchial carcinoma cell type. Thorax. 1982, 37: 462-465.PubMedPubMedCentralCrossRef
18.
go back to reference Clee MD, Duguid HL, Sinclair DJ: Accuracy of morphological diagnosis of lung cancer in a department of respiratory medicine. J Clin Pathol. 1982, 35: 414-419.PubMedPubMedCentralCrossRef Clee MD, Duguid HL, Sinclair DJ: Accuracy of morphological diagnosis of lung cancer in a department of respiratory medicine. J Clin Pathol. 1982, 35: 414-419.PubMedPubMedCentralCrossRef
19.
go back to reference Payne CR, Hadfield JW, Stovin PG, Barker V, Heard BE, Stark JE: Diagnostic accuracy of cytology and biopsy in primary bronchial carcinoma. J Clin Pathol. 1981, 34: 773-778.PubMedPubMedCentralCrossRef Payne CR, Hadfield JW, Stovin PG, Barker V, Heard BE, Stark JE: Diagnostic accuracy of cytology and biopsy in primary bronchial carcinoma. J Clin Pathol. 1981, 34: 773-778.PubMedPubMedCentralCrossRef
20.
go back to reference Arinç S, Saltürk C, Ertuğrul M, Sulu E, Tuncer L, Nergis S, Selvi U: Cell type agreement between bronchoscopic biopsy and thoracotomy specimens in primary lung cancer. Tuberk Toraks. 2007, 55: 378-382.PubMed Arinç S, Saltürk C, Ertuğrul M, Sulu E, Tuncer L, Nergis S, Selvi U: Cell type agreement between bronchoscopic biopsy and thoracotomy specimens in primary lung cancer. Tuberk Toraks. 2007, 55: 378-382.PubMed
21.
go back to reference Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM: Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010, 5: 442-447.PubMedCrossRef Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM: Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010, 5: 442-447.PubMedCrossRef
22.
go back to reference Sigel CS, Moreira AL, Travis WD, Zakowski MF, Thornton RH, Riely GJ, Rekhtman N: Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol. 2011, 6: 1849-1856.PubMedCrossRef Sigel CS, Moreira AL, Travis WD, Zakowski MF, Thornton RH, Riely GJ, Rekhtman N: Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol. 2011, 6: 1849-1856.PubMedCrossRef
23.
go back to reference Shi Y, Wu H, Zhang M, Ding L, Meng F, Fan X: Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma. Diagn Pathol. 2013, 8: 89-doi:10.1186/1746-1596-8-89PubMedPubMedCentralCrossRef Shi Y, Wu H, Zhang M, Ding L, Meng F, Fan X: Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma. Diagn Pathol. 2013, 8: 89-doi:10.1186/1746-1596-8-89PubMedPubMedCentralCrossRef
24.
go back to reference Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, Ma Y, Wang H, Zang W, Zhang G, Zhao G: Analysis of MAT3 gene expression in NSCLC. Diagn Pathol. 2013, 9 (8): 166-doi:10CrossRef Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, Ma Y, Wang H, Zang W, Zhang G, Zhao G: Analysis of MAT3 gene expression in NSCLC. Diagn Pathol. 2013, 9 (8): 166-doi:10CrossRef
25.
go back to reference Xiong Y, Bai Y, Leong N, Laughlin TS, Rothberg PG, Xu H, Nong L, Zhao J, Dong Y, Li T: Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol. 2013, 8 (1): 27-Epub ahead of printPubMedPubMedCentralCrossRef Xiong Y, Bai Y, Leong N, Laughlin TS, Rothberg PG, Xu H, Nong L, Zhao J, Dong Y, Li T: Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol. 2013, 8 (1): 27-Epub ahead of printPubMedPubMedCentralCrossRef
26.
go back to reference Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W, Otterson GA: Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. Diagn Pathol. 2013, 8: 201-doi:10.1186/1746-1596-8-201PubMedPubMedCentralCrossRef Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W, Otterson GA: Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. Diagn Pathol. 2013, 8: 201-doi:10.1186/1746-1596-8-201PubMedPubMedCentralCrossRef
27.
go back to reference Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010, 362: 2380-2388.PubMedCrossRef Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010, 362: 2380-2388.PubMedCrossRef
28.
go back to reference Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 2010, 11: 121-128.PubMedCrossRef Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 2010, 11: 121-128.PubMedCrossRef
29.
go back to reference Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, De Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC): A multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012, 13: 239-246.PubMedCrossRef Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, De Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC): A multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012, 13: 239-246.PubMedCrossRef
30.
go back to reference Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010, 363: 1693-1703.PubMedPubMedCentralCrossRef Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010, 363: 1693-1703.PubMedPubMedCentralCrossRef
31.
go back to reference Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M: Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011, 6: e20351-PubMedPubMedCentralCrossRef Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M: Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011, 6: e20351-PubMedPubMedCentralCrossRef
32.
go back to reference Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, et al.: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011, 1: 78-89.PubMedPubMedCentralCrossRef Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, et al.: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011, 1: 78-89.PubMedPubMedCentralCrossRef
33.
go back to reference Kayser K, Fritz P, Drlicek M, Rahn W: Expert consultation by use of telepathology–the Heidelberg experiences. Anal Cell Pathol. 1995, 9: 53-60.PubMed Kayser K, Fritz P, Drlicek M, Rahn W: Expert consultation by use of telepathology–the Heidelberg experiences. Anal Cell Pathol. 1995, 9: 53-60.PubMed
Metadata
Title
Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma
Authors
Tomoko Yamagishi
Katsuhiko Shimizu
Nobuaki Ochi
Hiromichi Yamane
Isao Irei
Yoshito Sadahira
Nagio Takigawa
Mikio Oka
Masao Nakata
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2014
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-9-103

Other articles of this Issue 1/2014

Diagnostic Pathology 1/2014 Go to the issue